Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,050 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Melanoma (Skin) Clear all

Conditions: Melanoma
Interventions: Immunotherapy, Quality-of-Life Assessment, Radiation Therapy; Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Jacksonville, Florida • Camden, New Jersey • Houston, Texas

Conditions: Melanoma
Interventions: 6MHP, Montanide ISA-51, polyICLC, Cyclophosphamide; Biological · Drug
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Melanoma
Interventions: melanoma GVAX, Cyclophosphamide; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Melanoma, Skin Cancer, Neoplasm
Interventions: ADI PEG 20; Drug
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: New York, New York

Conditions: Melanoma
Interventions: gp100, R848 gel, MAGE-3; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer
Interventions: PF-07921585, Sasanlimab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more

Conditions: Melanoma
Interventions: TLPLDC, Placebo; Drug
Lead sponsor: Elios Therapeutics, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 15 more

Conditions: Malignant Melanoma Stage IV
Interventions: DC Vaccine & Cyclophosphamide, DC Vaccine & Placebo; Biological
Lead sponsor: Baylor Research Institute; Other
Eligibility: 21 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Melanoma
Interventions: Ipilimumab, Nivolumab, Tocilizumab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York

Conditions: Melanoma and Metastatic Colorectal Cancer
Interventions: LGX818; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 5
States / cities: Tampa, Florida • Boston, Massachusetts

Conditions: Cancer
Interventions: GSK1120212; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • New York, New York + 3 more

Conditions: Malignant Melanoma
Interventions: Vincristine Sulfate Liposomes Injection; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Interventions: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab; Biological
Lead sponsor: Simcha IL-18, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Melanoma
Interventions: Poly ICLC, leukapheresis; Drug · Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Melanoma
Interventions: administration of ipilimumab10mg/kg, administration of ipilimumab 3mg/kg + HDI; Drug
Lead sponsor: Diwakar Davar; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
Interventions: IFx-Hu2.0; Biological
Lead sponsor: TuHURA Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Melanoma, Metastatic Melanoma
Interventions: SAbR, Ipilimumab, Nivolumab; Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Melanoma
Interventions: Vigil™ Vaccine; Biological
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Melanoma
Interventions: Pembrolizumab; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma
Interventions: Nivolumab - Arm A, Nivolumab + Ipilimumab - Arm B; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Melanoma
Interventions: GME751, Keytruda - EU, Keytruda - US; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Orange, California • Clermont, Florida • Orange City, Florida

Conditions: Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
Interventions: Phase 1b: APG-115+pembrolizumab; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 17
States / cities: Tucson, Arizona • Rogers, Arkansas • Los Angeles, California + 14 more

Conditions: Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Aldesleukin, Laboratory Biomarker Analysis, Ziv-Aflibercept; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 17 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 21
States / cities: Duarte, California • Sacramento, California • South Pasadena, California + 14 more

Conditions: Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
Interventions: Radiotherapy, MEDI4736, Tremelimumab; Radiation · Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma

Study of ADI-PEG 20 in Patients With Advanced Melanoma

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

Phase IIB TL + YCWP + DC in Melanoma

Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma

pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma

SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients

Phase II FANG™ in Advanced Melanoma

Imaging FDG Flare in Melanoma

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers